Since 2014, Sen-Jam has been driven to revolutionize pain management - to usher in a new dawn for all of full strength living

Sen-Jam has been working hard amassing 24 both domestic and international patents and patents pending

  • April

    Listed on RedCrow’s Equity CrowdFunding site

  • April

    Sen-Jam featured in StartUp Healths Insights

  • March

    Alcohol Hangover Paper Published featuring SJP-001

  • March

    Off-Label use of our Opioid Withdrawal Product used in tapering Suboxone

  • January

    Sen-Jam participates in StartUp Health Festival during JP Morgan Health Conference

    2020

  • Fall

    Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder

  • November

    Presented at Life Science Summit, NYC

  • Fall

    Patent issued for SJP-001

  • September

    Led panel discussion for Opioid Crisis Working Group
  • August

    Highlighted in Real Leaders Magazine for work related to opioid withdrawal
  • July

    Op Ed published in StartUp Health Magazine

  • June

    Partnered with Stony Brook University - Center for Biotechnology

  • Spring

    Conducted additional pre-clinical studies for opioid withdrawal (SJP-005)

  • January

    Sen-Jam participates in StartUp Health Festival, the premier forum of Health Transformers during JP Morgan Health Conference

    2019

  • Fall

    Sen-Jam attends RESI conference and pushes greater insight on Opioid Use Disorder

  • June

    Sen-Jam attends Research Society on Alcoholism Conference

  • May

    Sen-Jam attends BioTech event at Cold Spring Harbor Labs

  • Spring

    Spring pre-clinical studies for opioid withdrawal (SJP-005)

  • March

    Sen-Jam files patent for treatment of enteropathic arthritis (SJP-004)

  • January

    Sen-Jam attends JP Morgan Health Conference

    2018

  • November

    Sen-Jam Wins RESI Innovation Challenge

  • October

    Sen-Jam first Corporate Retreat

  • September

    Sen-Jam files patents to inhibit symptoms associated with opioid withdrawal (SJP-005), opioid dependence (SJP-006), and opioid tolerance (SJP-007)

  • August

    Sen-Jam files patent to inhibit adverse effects associated with vaccinations (SJP-003)

  • August

    Sen-Jam Pharmaceutical LLC is formed

  • July

    Sen-Jam attends Research Society on Alcoholism Conference

  • June

    Investigational New Drug (IND) application opened with the FDA to begin Phase I Clinical Trial

  • June

    Sen-Jam files patent to inhibit symptoms associated with Viral Respiratory Infections (SJP-002)

  • April

    Sen-Jam presents in Amsterdam at 9th annual Alcohol Hangover Research Group Conference

    2017

  • October

    Sen-Jam completes Pre-Investigational new drug meeting with FDA

  • August

    Trademarks filed & Scientific Advisory Board established

  • June

    Sen-Jam presents findings to Alcohol Hangover Research Group at National Institute on Alcohol Abuse and Alcoholism Conference

  • March

    Conducted IRB Study for Prevention of Alcohol Hangover (SJP-001)

    2016

  • March

    Provisional Patents Filed

    2015

  • Fall

    Volunteer Study Begins—SJP-001

  • Spring

    Jackie Iversen has Eureka moment

    2014